Jim Olson - Xconomy

by in

Entry	Author	Date	Location
Presage Snags $13M from Celgene to Pick Winning Cancer Drug Combos	Luke Timmerman	03/05/13	Seattle
Blaze Bioscience Caps Off $8.5M Financing, Charges Toward Clinic	Luke Timmerman	02/22/13	Seattle
Fred Hutch Spinoff Blaze Bioscience Pulls in $5M For ‘Tumor Paint’	Luke Timmerman	06/08/12	Seattle
Presage Looks to Help Millennium Pick Cancer Drug Winners Early	Luke Timmerman	04/06/12	Seattle
Hutch Spinoff Presage Biosciences Shuffles Management	Luke Timmerman	12/15/11	Seattle
Blaze Bioscience, Fred Hutch Spinoff with Zymo Vet at the Helm, Seeks to “Paint” Tumors	Luke Timmerman	10/18/11	Seattle
PhaseRx Angles for a Deal, Tom Clement’s New Device Gig(s), InDi’s Alzheimer’s Plan, & More in the Life Science Innovation Northwest Wrap-Up	Luke Timmerman	03/04/11	Seattle
Presage Biosciences, the Fred Hutch Spinoff, Adds CEO, Angel Bucks, Big Pharma Customers	Luke Timmerman	06/23/10	Seattle
Google Apps Teams Up with Local Firms, Evri and Twine Merge, WildTangent Goes Social, & More Seattle-Area Deals News	Gregory T. Huang	03/16/10	Seattle
Presage, a Hutch Spinoff, Raises $3M From Angels to Boost Cancer Drug Hit Rate	Luke Timmerman	03/16/10	Seattle
Dendreon’s Manufacturing Challenge, Archus Cuts Deep, Accelerator Company Launches & More Seattle-Area Life Sciences News	Luke Timmerman	05/21/09	Seattle
Presage, Fred Hutch Spinoff, Aims to Show Docs Which Cancer Drugs Work, and Which Won’t	Luke Timmerman	05/19/09	Seattle
Page 1 of 1

Xconomy National